Novo Nordisk A S (NONOF) stock
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S grew revenue 6.4% to 309.06B DKK over fiscal 2025. Operating income fell 0.5% to 127.66B DKK, moving the operating margin from 44.2% to 41.3%. Free cash flow was 58.96B DKK, down 20.1% from a year earlier. At the latest close the market valued the company at 1.14T DKK, 11.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- 1.14T DKK
- P/E ratio
- 11.1
- Price to sales
- 3.70
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 5.16%
Fundamentals
- Revenue
- 309.06B DKK
- EPS, diluted
- 23.03 DKK
- Free cash flow
- 58.96B DKK
Trading
- Previous close
- $38.84
- Open
- $37.59
- Day's range
- $37.25 – $39.17
- Volume
- 12,322
- Average volume (20 days)
- 155,727
- Beta (5 years)
- 0.76
- RSI (14 days)
- 54.6
- Volatility (1 year)
- 45.6%
- Relative volume
- 1.02×
- WACC
- 8.2%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | NONOF | S&P 500 | Difference | NONOF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.3% | +0.6% | −10.9 pts | ||
| 3 months | -24.6% | +3.4% | −28.0 pts | ||
| Year to date | -22.5% | +13.3% | −35.7 pts | ||
| 1 year | -28.1% | +16.6% | −44.8 pts | ||
| 3 years | -58.0% | +86.4% | −144.4 pts | -25.1% | +23.1% |
| 5 years | -21.1% | +81.9% | −102.9 pts | -4.6% | +12.7% |
| 10 years | +133.8% | +318.9% | −185.0 pts | +8.9% | +15.4% |
Twelve years at a glance
Fiscal years 2014 to 2025, DKK
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
About Novo Nordisk A S
Pharmaceutical Preparations
Novo Nordisk A/S is a global healthcare company specializing in the discovery, development, manufacturing, and marketing of pharmaceutical products. The company operates primarily through two core segments: Obesity and Diabetes care, and Rare disease. Its portfolio features glucagon-like-peptide-1 (GLP-1) receptor agonists and insulins for metabolic conditions, alongside treatments for haemophilia and growth hormone deficiencies. These prescription medicines and medical devices primarily serve patients living with chronic conditions, as well as healthcare practitioners and clinical facilities.
Company profile, executives and historyNovo Nordisk A S stock: common questions
What is Novo Nordisk A S's stock price?
NONOF closed at $38.24 on Oct 19, 2026, down 1.53% on the day.
What is Novo Nordisk A S's market cap?
Novo Nordisk A S was worth $170.76B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is NONOF's P/E ratio?
NONOF trades at 11.1 times earnings, based on diluted earnings per share of 23.03 DKK over fiscal 2025.
How much revenue does Novo Nordisk A S make?
Novo Nordisk A S reported revenue of 309.06B DKK for fiscal 2025, up 6.4% from a year earlier.
Does Novo Nordisk A S pay a dividend?
No. Novo Nordisk A S has not paid a cash dividend over the last twelve months.
How has NONOF stock performed over the past year?
Including dividends, NONOF returned -28.1% over the past year, against +16.6% for the S&P 500.
Who are Novo Nordisk A S's competitors?
Companies most similar to Novo Nordisk A S by business, industry and size include LLY, RDY, ABT, JNJ, MRK.
See a number that looks wrong?